Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Prof Wynand Goosen
Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards.

Being nominated for a ‘Science Oscar’ is exciting and validates nominees’ efforts, particularly in a field as challenging and essential as infectious diseases, for which they are recognised at the highest level. 

This is according to Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State (UFS). He was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards for his landmark discovery of Mycobacterium bovis infection in humans in South Africa – the first confirmed cases in the country. 

Prof Goosen, who previously won the NSTF-South32 Emerging Researcher Award, says the nomination is a powerful affirmation of the impact that focused, interdisciplinary research can have. It reflects not only his personal commitment but also the dedication of a talented and hard-working team. “I am honoured and humbled to be nominated. It is also a testament to the support and vision of UFS, particularly as we position ourselves as leaders in One Health research in South Africa,” he says. 

 

Focus of research 

He was nominated by Prof Vasu Reddy, UFS Deputy Vice-Chancellor: Research and Internationalisation, and Prof Paul Oberholster, Dean for the Faculty of Natural and Agricultural Sciences (NAS) at the UFS, and Prof Nico Gey van Pittius and Prof Elmi Muller from Stellenbosch University (US). The NSTF Awards, known as the ‘Science Oscars’of SA, honour, reward, celebrate, profile and promote outstanding contributions to science, engineering and technology (SET) and innovation in South Africa.

“The nomination,” Prof Goosen continues, “recognises our work in the field of zoonotic tuberculosis (TB) and other emerging infectious diseases at the human-animal-environment interface. Our research focuses on the molecular detection and characterisation of pathogenic mycobacteria in wildlife, livestock, and human populations, with the aim of informing better surveillance, diagnostics, and control strategies — particularly in high-risk ecosystems. This includes novel applications in wildlife TB surveillance and understanding the transmission dynamics between animals and people.”

 

Establishing a Kovsie One Health Research Unit

This research is critically important as South Africa continues to face a high burden of tuberculosis, including zoonotic TB, which often goes under-detected in rural and wildlife-rich areas. Understanding how these pathogens circulate between humans, animals, and the environment, explains Prof Goosen, is essential for effective disease control and to mitigate future pandemics. This work directly supports national health priorities, informs policy, and contributes to global strategies for One Health.

Prof Goosen and the team are in the process of laying the groundwork for the establishment of a Kovsie One Health Research Unit, which will serve as a collaborative platform for research spanning human, animal, and environmental health. One of their key projects involves expanding TB and AMR surveillance in wildlife-livestock-human interfaces, using cutting-edge diagnostics and genomic tools. They are also initiating partnerships with industry and international institutions to address emerging zoonoses and environmental pathogens in a transdisciplinary manner.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept